Two Never-Smokers, husband and wife. Two Diagnoses: Stage I vs. Stage IV—The Difference Was One CEA  Blood Test

 The absence of screening in never-smokers represents a critical blind spot in lung cancer care. 

 Without That Test, His Lung Cancer Would Have Gone Undetected.

 
Help me Close this Gap in Lung Cancer Detection.

This is my story: From September 2022 to May 2024, I was misdiagnosed with Ménière’s disease.
The reality was uncovered too late—stage 4 lung cancer.

During that time, I was never evaluated using biomarkers that, life insurance companies are using to assess risk. The delay in diagnosis reflects a broader issue: early warning signals are often not investigated in patients considered “low risk.” The never-smokers are simply never tested for lung cancer. My neurosurgeon later told me that he sees this pattern too often—patients diagnosed with Ménière’s disease when, in some cases, it is cancer presenting in disguise.  I promised myself during those 18 days at the  hospital fighting between life and death, that I was going to beat it for my family, my teens still need me, and that if I made it I was going to fight with all my mighty to find biomarker testing to help other people, to detect it at early stages instead of stage 4.

Then the unspeakable happen, my husband went to get life insurance,  he got denied because his Carcinoembryonic Antigen (CEA) levels were elevated.  Which prompted further evaluation and helped identify his condition early enough for surgical intervention, lung cancer stage 1.

It all came rushing to my head, do you remember when at the hospital I said I would not stop until we found a biomarker to detect cancer before it became stage 4? Well, that is how, CarcinoEmbryonic Antigen CEA landed in my hands.  That prompted the investigation and how we found his cancer. Without that test initiated by life insurance he would never have known.

Thus commenced my formal investigation into CEA, marking the transition from curiosity to structured inquiry. 

We have measurable signals, but no unified approach to act on them. A simple $25-40 blood work could tell you, you need to investigate.

The Gap in Early Detection
Only about 20% of lung cancers are diagnosed at stage I.
In the non-smokers, the majority +55%, including my case, are diagnosed at stage IV.

Lung cancer remains the leading cause of cancer-related death. Approximately 15–25% of cases occur in never-smokers—yet there are no established screening pathways for this population.

CEA has long been dismissed as insufficiently specific for screening. That is understood. However, in the right clinical context—particularly in otherwise healthy, non-smoking individuals—an elevated CEA should not be automatically disregarded. It may not point to one specific cancer, so a false postive for lung cancer, may be a positive for colon or other cancers, but it is rarely without meaning, why discard such valuable information?

The goal is not to rely on a single test, but to recognize when the body is signaling that something may be wrong—and to investigate accordingly.

 
A Call for Action
To the National Cancer Institute, the Centers for Medicare & Medicaid Services, the U.S. Preventive Services Task Force, and policymakers including Alex Padilla:

Prioritize prospective clinical studies evaluating biomarkers such as CEA in non-smoking, otherwise healthy populations
Ensure equitable access to biomarker testing and transparency in how such data is used across healthcare and insurance systems
Consider integrating emerging biomarker evidence into future screening frameworks
If a signal exists, patients deserve the opportunity to understand it—and act on it.

 
Beyond Detection: The Need for Better Therapies
While targeted therapies and immunotherapies have advanced, lung cancer outcomes—particularly in advanced stages—still lag behind other major cancers. Durable remission remains uncommon for many patients, highlighting the urgent need for:

-Earlier detection strategies
-More effective, personalized treatments
-Increased research investment across diverse patient populations, including never-smokers
 
Conclusion
Lung cancer is often called the silent killer.
Early detection is the only way to change that.

The current guidelines recommend mammograms, pap-smears, for females,  PSA levels for males,  colonoscopies for anyone above 40, yet nothing for the non-smokers for their lungs.

We are not asking for overtesting—we are asking for alignment, transparency, and the willingness to investigate when signals appear.

Because the difference between early and late diagnosis is not always the absence of data.
Sometimes, it is whether we choose to act on it.

 
Join the Movement
Stand up against the silent killer.
Support awareness, transparency, and earlier detection.

Together, we can change outcomes.

DO NOT pay money to promote this petition as that DOESN'T WORK,  just share.

For funding use  the Lung Cancer Research Association or DM via Instagram: 

https://give.lungcancerresearchfoundation.org/team/820050